NCCN GUIDELINES® INSIGHTS: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. LangTamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Ryan A. Berardi, Dorothy A. Shead, Deborah A. Freedman-Cass

Research output: Contribution to journalArticlepeer-review

150 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

Original languageEnglish
Pages (from-to)1288-1298
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number12
DOIs
StatePublished - Dec 2022

Fingerprint

Dive into the research topics of 'NCCN GUIDELINES® INSIGHTS: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this